Reuters logo
BRIEF-Revance provides financial outlook for 2017
January 5, 2017 / 9:35 PM / a year ago

BRIEF-Revance provides financial outlook for 2017

Jan 6 (Reuters) - Revance Therapeutics Inc

* Revance provides clinical milestones and financial outlook for 2017

* Revance Therapeutics Inc - three clinical trials expected to report results in 2017

* Revance Therapeutics Inc - company also announced its unaudited December 31, 2016 cash and investments balance was $185 million

* Revance Therapeutics Inc - now expects its cash and investments to fund company into q3 of 2018

* Revance Therapeutics Inc - expects cash burn for 2017 to be in range of $102 to $112 million

* Revance Therapeutics Inc - expects 2017 gaap operating expense to be in range of $108 to $119 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below